AI Article Synopsis
Article Abstract
Multiple myeloma, a malignant neoplasm of plasma cells that accumulate in bone marrow, accounts for approximately 18% of hematologic malignancies in the United States. Patients are often treated with triplet therapy and may undergo stem cell transplantation. Despite effective therapies, multiple myeloma remains incurable. Patients often require maintenance therapy, and many will progress or relapsed following upfront treatment. Selection of treatment in the relapse/refractory setting is complex due numerous active therapeutic agents and combinations. Treatment is often tailored to prior exposure and duration. In 2020, three novel pharmacological agents were approved in the relapsed setting. We highlight the clinical safety and efficacy of selinexor, isatuximab-irfc, and belantamab mafodotin for patients with multiple myeloma.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1177/10781552211028906 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Nivolumab to restore T-cell fitness in CAR-T refractory multiple myeloma.
Blood Adv
January 2025
Harvard Medical School, United States.
Efficacy and durability remain central shortcomings of T-cell based therapies in multiple myeloma (MM). Here, we employ blood-based transcriptional T-cell profiling to define impaired T-cell fitness as putative biomarker associated with sensitivity to PD1 inhibition in CAR-T refractory MM patients.
View Article and Find Full Text PDFCurrent developments in T-cell receptor therapy for Acute Myeloid Leukaemia.
Blood Adv
January 2025
The University of Sydney, Sydney, Australia.
T-cell receptor (TCR) therapies are a promising modality for the treatment of cancers, with significant efforts being directed towards acute myeloid leukaemia (AML), a particularly challenging disease. Chimeric antigen receptor (CAR) T-cells targeting single surface antigens have shown remarkable efficacy for B-cell lymphoblastic leukaemia, lymphomas and multiple myeloma. However, AML presents formidable obstacles to the effectiveness of CAR T-cells due to the widespread expression of heterogenous leukaemia immunophenotypes and surface antigen targets additionally present on normal myeloid cells.
View Article and Find Full Text PDFLevel of Clonal Plasma Cells in Hematopoietic Cell Autografts Reflects the Pre-Transplant Bone Marrow Minimal Residual Disease in Multiple Myeloma Patients.
Am J Hematol
January 2025
Department of Hematooncology, University Hospital Ostrava, Ostrava, Czech Republic.
Diagnostic d'un myélome multiple à immunoglobuline D Lambda avec une atteinte rénale sévère 10 ans après un plasmocytome solitaire : Un cas clinique et revue de la littérature.
Tunis Med
January 2025
Department of Nephrology, Dialysis, and Transplantation, Hedi Chaker University Hospital, Sfax, Tunisia.
Introduction: Immunoglobulin D (IgD) myeloma is a rare subtype often described as aggressive with advanced disease at diagnosis. Primary renal involvement is seen in scarce cases.
Observation: This case features a 55-year-old man with IgD lambda myeloma presenting severe renal failure at diagnosis.
Retrospective claims data analysis of ASCT characteristics and costs for working-age, multiple myeloma patients in the US, 2017-2019.
Leuk Res Rep
December 2024
Department of Pharmaceutical Health Outcomes and Policy, University of Houston College of Pharmacy, United States.
Multiple myeloma (MM) is a rare hematologic malignancy with a 5-year survival rate of 52 %. For transplant-eligible MM patients, high-dose chemotherapy followed by autologous stem cell transplant (ASCT) is recommended. Given the complexities of the ASCT procedure, understanding patient-specific factors and their impact on treatment decisions is essential.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!